{"id":747196,"date":"2023-04-12T16:34:58","date_gmt":"2023-04-12T20:34:58","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/dbv-technologies-announces-results-of-its-2023-ordinary-and-extraordinary-general-meeting\/"},"modified":"2023-04-12T16:34:58","modified_gmt":"2023-04-12T20:34:58","slug":"dbv-technologies-announces-results-of-its-2023-ordinary-and-extraordinary-general-meeting","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/dbv-technologies-announces-results-of-its-2023-ordinary-and-extraordinary-general-meeting\/","title":{"rendered":"DBV Technologies Announces Results of its 2023 Ordinary and Extraordinary General Meeting"},"content":{"rendered":"
\n

Montrouge, France, April 12, 2023<\/p>\n

\n DBV Technologies Announces Results of its <\/strong>
\n 202<\/strong>
\n 3<\/strong>
\n Ordinary and Extraordinary General Meeting <\/strong>\n <\/p>\n

\n Shareholders <\/strong>
\n A<\/strong>
\n pprove<\/strong>
\n d<\/strong>
\n A<\/strong>
\n ll <\/strong>
\n P<\/strong>
\n roposed <\/strong>
\n R<\/strong>
\n esolutions<\/strong>\n <\/p>\n

DBV Technologies (Euronext: DBV \u2013 ISIN: FR0010417345 \u2013 Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today held its Ordinary and Extraordinary General Meeting. The General Meeting was chaired by Michel de Rosen, Chairman of DBV Technologies. <\/p>\n

The Company\u2019s shareholders approved all resolutions submitted by the Board of Directors. These resolutions and their results are posted on the Investors<\/a>\/Annual General Meetings<\/a> section<\/a> of the Company\u2019s website: https:\/\/www.dbv-technologies.com\/events\/2023-annual-general-meeting\/<\/a>. <\/p>\n

\n About DBV<\/strong>
\n Technologies\u00a0<\/strong>
\n
DBV Technologies is developing Viaskin\u2122, an investigational proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT\u2122, and is DBV Technologies\u2019 method of delivering biologically active compounds to the immune system through intact skin. With this new class of non-invasive product candidates, the Company is dedicated to safely transforming the care of food allergic patients. DBV Technologies\u2019 food allergies programs include ongoing clinical trials of Viaskin Peanut. DBV Technologies has global headquarters in Montrouge, France, and North American operations in Basking Ridge, NJ. The Company\u2019s ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345) and the Company\u2019s ADSs (each representing one-half of one ordinary share) are traded on the Nasdaq Global Select Market (Ticker: DBVT).<\/p>\n

\n Investor Contact <\/strong>
\n
Anne Pollak
DBV Technologies
+1 857-529-2363
anne.pollak@dbv-technologies.com<\/u><\/a><\/p>\n

\n Media Contact<\/strong>
\n
Angela Marcucci
DBV Technologies
+1\u00a0646-842-2393<\/p>\n

\n angela.marcucci@dbv-technologies.com<\/u>\n <\/p>\n

\n

\n Attachment<\/strong>\n <\/p>\n